# US 2025/0205347 A1 · Methods for treating inflammatory conditions of the eye with an igf-1r ligand conjugated to a disease-modifying agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205347 A1
- Document ID: US20250205347A1
- Status: Published application
- Kind: A1
- Application number: 18/876,858
- Filed: 2023-06-29
- Published: 2025-06-26
- Earliest claimed: 2022-06-29
- Assignees: Lirum Therapeutics, Inc.
- Applicants: Lirum Therapeutics, Inc.
- Inventors: Matthew HOBERMAN
- Web page: https://patentgrep.com/patent/US20250205347A1

## CPC

- A61K 47/642: {the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for treating an inflammatory condition of the eye in a subject, comprising administering to the subject an effective amount of a conjugate that comprises an IGF-IR ligand, or portion or variant thereof, and a disease-modifying agent.

## Claims

### Claim 1

A method for treating an inflammatory condition of the eye in a subject in need thereof, said method comprising administering to the subject a conjugate comprising an insulin-like growth factor 1 receptor (IGF-1R) ligand, or portion or variant thereof, and a disease-modifying agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein said inflammatory condition of the eye is selected from the group consisting of thyroid eye disease (TED), uveitis, scleritis, keratitis, conjunctivitis, and an orbital inflammatory disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein said orbital inflammatory disease is selected from the group consisting of idiopathic orbital inflammation, orbital inflammatory pseudotumor, orbital myositis, inflammatory orbital cellulitis, optic perineuritis, periscleritis, diffuse orbital inflammation, orbital apicitis, and sclerosing orbital inflammation.

### Claim 4 (depends on 2)

The method of claim 2, wherein said inflammatory condition of the eye is TED.

### Claim 5 (depends on 4)

The method of claim 4, wherein said TED is selected from the group consisting of active TED, acute TED, inactive TED, chronic TED, moderate-to-severe TED, and sight-threatening TED.

### Claim 6 (depends on 4, 5)

The method of claim 4 or 5, wherein said method results in a reduction in proptosis in said subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein proptosis is reduced by at least 2 mm, at least 3 mm, or at least 4 mm.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein said reduction in proptosis is assessed by exophthalmometer or orbital imaging.

### Claim 9 (depends on 8)

The method of claim 8, wherein said orbital imaging is computerized tomography (CT) scan or magnetic resonance imaging.

### Claim 10 (depends on 6, 7, 8, 9)

The method of any one of claims 6-9, wherein the reduction in proptosis is associated with a reduction in extraocular muscle volume.

### Claim 11 (depends on 6, 7, 8, 9)

The method of any one of claims 6-9, wherein the reduction in proptosis is associated with a reduction in orbital fat volume.

### Claim 12 (depends on 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 4-11, wherein said method results in a reduction in the clinical activity score (CAS) in said subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the CAS is reduced by at least 2 points or at least 3 points.

### Claim 14 (depends on 12)

The method of claim 12, wherein the CAS is reduced to 1 or reduced to 0.

### Claim 15 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 4-14, wherein said method results in a reduction in the severity of diplopia in said subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein said reduction in the severity of diplopia is measured by a Gorman subjective diplopia score.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein said diplopia is selected from the group consisting of constant diplopia, intermittent diplopia, and inconstant diplopia.

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein said method results in complete resolution of diplopia.

### Claim 19 (depends on 16, 17, 18)

The method of any one of claims 16-18, wherein the severity of diplopia in the subject is reduced by at least one grade.

### Claim 20 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 4-19, wherein said method results in an improvement in the quality of life of said subject.

### Claim 21 (depends on 20)

The method of claim 20, wherein said improvement in the quality of life is measured by a Graves' Ophthalmopathy Quality of Life (GO-QoL) assessment scale.

### Claim 22 (depends on 20, 21)

The method of claim 20 or 21, wherein said quality of life is measured by a Visual Functioning subscale or an Appearance subscale of the GO-QoL.

### Claim 23 (depends on 21, 22)

The method of claim 21 or 22, wherein said quality of life is improved by at least 8 points.

### Claim 24 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 4-23, wherein said method results in an improvement in optic neuropathy.

### Claim 25 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 4-24, wherein said method results in a reduction in retro-orbital edema.

### Claim 26 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 4-25, wherein said method results in an improvement in monocular ductions.

### Claim 27 (depends on 26)

The method of claim 26, wherein said improvement in monocular ductions is measured by a light reflex test.

### Claim 28 (depends on 27)

The method of claim 27, wherein said improvement is of at least 10 degrees.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein said subject has a reduction in a number of IGF-1R expressing cells.

### Claim 30 (depends on 29)

The method of claim 29, wherein the reduction in the number of IGF-IR-expressing cells is measured by flow cytometry or immunohistochemistry.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein said IGF-1R-expressing cells are orbital fibroblasts (OFs).

### Claim 32 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 4-31, wherein said method results in reduction or inhibition of hyaluronan synthesis in a retro-ocular space.

### Claim 33 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 4-32, wherein said method results in reduction or inhibition of adipogenesis or a reduction in adipocytes in the retro-ocular space of said subject.

### Claim 34 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 4-33, wherein said method results in reduction in the level of interleukin (IL)-6, IL-16, and/or RANTES in the serum of said subject.

### Claim 35 (depends on 29, 30)

The method of claim 29 or 30, wherein said IGF-1R-expressing cells are selected from the group consisting of fibrocytes, B lymphocytes, and T lymphocytes.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein said IGF-1R ligand comprises wildtype insulin-like growth factor 1 (IGF-1), wildtype insulin, or wildtype insulin-like growth factor 2 (IGF-2).

### Claim 37 (depends on 36)

The method of claim 36, wherein said wildtype IGF-1 comprises SEQ ID NO:3, wherein said wildtype insulin comprises SEQ ID NO: 10 or 11, and wherein said wildtype IGF-2 comprises SEQ ID NO:12.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, wherein said IGF-1R ligand comprises a variant of wildtype IGF-1, a variant of wildtype insulin, or a variant of wildtype IGF-2.

### Claim 39 (depends on 38)

The method of claim 38, wherein said variant of wildtype IGF-1 is at least 90% identical to SEQ ID NO:3, said variant of wildtype insulin is at least 90% identical to SEQ ID NO: 10 or 11, and said variant of wildtype IGF-2 is at least 90% identical to SEQ ID NO:12.

### Claim 40 (depends on 38, 39)

The method of claim 38 or 39, wherein: (i) said variant of wildtype IGF-1 has reduced binding affinity for insulin-like growth factor binding proteins (IGFBPs) as compared to wildtype IGF-1, or said variant of wildtype IGF-2 has reduced binding affinity for IGFBPs as compared to wildtype IGF-2, and/or (ii) said variant of wildtype IGF-1 has increased affinity for the IGF-1R as compared to wildtype IGF-1 or said variant of wildtype IGF-2 has increased affinity for the IGF-1R as compared to wildtype IGF-2.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 1-40, wherein said IGF-1R ligand, or portion or variant thereof, comprises a leader sequence.

### Claim 42 (depends on 41)

The method of claim 41, wherein said leader sequence comprises SEQ ID NO:1.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 38, 39, 40, 41, 42)

The method of any one of claims 1-35 and claims 38-42, wherein said IGF-1R ligand comprises 765IGF (SEQ ID NO:2), IGF-132 (SEQ ID NO:4), long-R3-IGF-1 (SEQ ID NO:5), R3-IGF-1 (SEQ ID NO:6), des(1-3)-IGF-1 (SEQ ID NO:7), long-IGF-1 (SEQ ID NO:8), or long-G3-IGF-1 (SEQ ID NO:9).

### Claim 44 (depends on 43)

The method of claim 43, wherein said IGF-1R ligand comprises 765IGF (SEQ ID NO:2).

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the IGF-1R ligand, or portion or variant thereof, is covalently bound to said disease-modifying agent, wherein said disease-modifying agent comprises a cytotoxic agent.

### Claim 46 (depends on 45)

The method of claim 45, wherein said cytotoxic agent comprises a chemotherapeutic agent.

### Claim 47 (depends on 46)

The method of claim 46, wherein said chemotherapeutic agent is amsacrine, azacytidine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, dactinomycin, daunorubicin, decarbazine, docetaxel, doxorubicin, epirubicin, estramustine, etoposide, floxuridine, fludarabine, fluorouracil, gemcitabine, hexamethylmelamine, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin C, mitotane, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, pentostatin, plicamycin, procarbazine, ralitrexed, semustine, streptozocin, temozolamide, teniposide, thioguanine, thiotepa, topotecan, trimitrexate, valrubicin, vincristine, vinblastine, vindestine, or vinorelbine.

### Claim 48 (depends on 47)

The method of claim 47, wherein said chemotherapeutic agent is methotrexate.

### Claim 49 (depends on 45)

The method of claim 45, wherein said cytotoxic agent comprises a toxin.

### Claim 50 (depends on 49)

The method of claim 49, wherein said toxin comprises Clostridium perfringens enterotoxin, diphtheria toxin, ricin chain A, Pseudomonas exotoxin, A chain toxins, a ribosome inactivating protein, α-sarcin, aspergillin, or a ribonuclease.

### Claim 51 (depends on 50)

The method of claim 50, wherein said toxin comprises Clostridium perfringens enterotoxin, or a portion or variant thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein the conjugate comprises SEQ ID NO:14 or SEQ ID NO: 15.

### Claim 53 (depends on 50)

The method of claim 50, wherein said toxin comprises diphtheria toxin, or a portion or variant thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein the toxin comprises SEQ ID NO: 13 or SEQ ID NO:16.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein said disease-modifying agent is selected from the group consisting of glucocorticoids, corticosteroids, a thyroid-stimulating hormone receptor (TSHR) inhibitor, mycophenolate mofetil, simvastatin, metformin, phenformin, cyclosporin, rapamycin, mammalian target of rapamycin (mTOR) inhibitors, and azathioprine.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 1-55, wherein said conjugate is administered at dose of about 0.05, 0.10, 0.20, 0.40, 0.80, 1.0, 1.5, 1.6, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 μEq/kg of body weight or at a dose range of about 0.05-0.5, 0.5-1.0, 1.0-1.5, 1.5-2.0, 2.0-2.5, 2.5-3.0, 3.0-3.5, 3.5-4.0, 4.0-4.5, 4.5-5.0, 5.0-5.5, 5.5-6.0, 6.0-6.5, 6.5-7.0, 7.0-7.5, 7.5-8.0, 8.0-8.5, 8.5-9.0, 9.0-9.5, or 9.5-10.0 μEq/kg of body weight.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 1-56, wherein said conjugate is administered at dose of about 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3. 5.4, 5.5, 5.6, 5.7, 5.8, 5.9. 6.0, 6.1, 6 2, 6.3, 6.4, 6.5. 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11.0, 11. 1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13.0, 13.1, 13 2, 13.3, 13 4, 13.5, 13.6, 13.7, 13.8, 13.9, 14.0, 14.1, 14.2, 14.3, 14.4, 14.5, 14.6, 14.7, 14.8, 14.9, 15.0, 15.1, 15.2, 15.3, 15.4, 15.5, 15.6, 15.7, 15.8, 15.9, 16.0, 16.1, 16.2, 16.3, 16.4, or 16.5 mg/kg of body weight or at a dose range of about 0.05-0.5, 0.5-1.0, 1.0-1.5, 1.5-2.0, 2.0-2.5, 2.5-3.0, 3.0-3.5, 3.5-4.0, 4.0-4.5, 4.5-5.0, 5.0-5.5, 5.5-6.0, 6.0-6.5, 6.5-7.0, 7.0-7.5, 7.5-8.0, 8.0-8.5, 8.5-9.0, 9.0-9.5, 9.5-10.0, 10.0-10.5, 10.5-11.0, 11.0-11.5, 11.5-12.0, 12.0-12.5, 12.5-13.0, 13.0-13.5, 13.5-14.0, 14.0-14.5, 14.5-15.0, 15.0-15.5, 15.5-16.0, or 16.0-16.5 mg/kg of body weight.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 1-57, wherein said conjugate is administered at dose that is the maximum tolerated dose.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 1-58, wherein said conjugate is administered daily, every other day, every three days, every four days, every five days, every six days, once per week, once every two weeks, once every three weeks, once every four weeks, once per month, every two months, or every three months.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein said conjugate is administered intravenously, subcutaneously, via intravitreal injection, via intra-orbital injection, or via eye dropper.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 1-35 and 38-60, wherein the IGF-IR ligand is SEQ ID NO: 2, the cytotoxic agent is methotrexate, wherein there are 6 to 10 methotrexate molecules for every IGF-1R ligand of SEQ ID NO:2, and the inflammatory condition of the eye is TED.
